| Drug General Information |
| Drug ID |
D0Q7LD
|
| Former ID |
DNC002645
|
| Drug Name |
2-Methyl-2-Propanol
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C4H10O
|
| Canonical SMILES |
CC(C)(C)O
|
| InChI |
1S/C4H10O/c1-4(2,3)5/h5H,1-3H3
|
| InChIKey |
DKGAVHZHDRPRBM-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
587060, 820565, 824488, 824493, 824495, 829409, 831395, 831718, 837274, 854655, 3132278, 6467454, 7890706, 8023088, 8154051, 10534928, 12079254, 14709186, 15146291, 17425442, 24851330, 24858660, 24859879, 24862169, 24867672, 24870757, 24873382, 24892081, 26697099, 26703480, 26706548, 26710884, 26719397, 29225374, 30964600, 37451913, 37609869, 37615327, 46507480, 48409757, 48409762, 48413335, 48414942, 48416814, 48420525, 48424140, 49854267, 57309692, 57323401, 57410735
|
| Target and Pathway |
| Target(s) |
Calmodulin |
Target Info |
Inhibitor |
[1]
|
|---|
| Methionine aminopeptidase 2 |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Calcium signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
cAMP signaling pathway
|
|
Phosphatidylinositol signaling system
|
|
Oocyte meiosis
|
|
Adrenergic signaling in cardiomyocytes
|
|
Vascular smooth muscle contraction
|
|
Circadian entrainment
|
|
Long-term potentiation
|
|
Neurotrophin signaling pathway
|
|
Dopaminergic synapse
|
|
Olfactory transduction
|
|
Phototransduction
|
|
Inflammatory mediator regulation of TRP channels
|
|
Insulin signaling pathway
|
|
GnRH signaling pathway
|
|
Estrogen signaling pathway
|
|
Melanogenesis
|
|
Oxytocin signaling pathway
|
|
Glucagon signaling pathway
|
|
Salivary secretion
|
|
Gastric acid secretion
|
|
Alzheimer's disease
|
|
Amphetamine addiction
|
|
Alcoholism
|
|
Pertussis
|
|
Tuberculosis
|
|
Glioma
|
|
NetPath Pathway
|
RANKL Signaling Pathway
|
|
TSH Signaling Pathway
|
|
PANTHER Pathway
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
BCR signaling pathway
|
|
p38 MAPK signaling pathway
|
|
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
|
|
Role of Calcineurin-dependent NFAT signaling in lymphocytes
|
|
IL2 signaling events mediated by PI3K
|
|
IFN-gamma pathway
|
|
Lissencephaly gene (LIS1) in neuronal migration and development
|
|
ErbB1 downstream signaling
|
|
VEGFR1 specific signals
|
|
Regulation of cytoplasmic and nuclear SMAD2/3 signaling
|
|
Calcium signaling in the CD4+ TCR pathway
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
Insulin-mediated glucose transport
|
|
N-cadherin signaling events
|
|
Cellular roles of Anthrax toxin
|
|
Regulation of Ras family activation
|
|
Downstream signaling in naï
|
|
PathWhiz Pathway
|
Muscle/Heart Contraction
|
|
Reactome
|
Calmodulin induced events
|
|
Platelet degranulation
|
|
Translocation of GLUT4 to the plasma membrane
|
|
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
|
|
DARPP-32 events
|
|
eNOS activation
|
|
Inactivation, recovery and regulation of the phototransduction cascade
|
|
FCERI mediated Ca+2 mobilization
|
|
Ca2+ pathway
|
|
CREB phosphorylation through the activation of CaMKII
|
|
Ras activation uopn Ca2+ infux through NMDA receptor
|
|
Smooth Muscle Contraction
|
|
VEGFR2 mediated vascular permeability
|
|
VEGFR2 mediated cell proliferation
|
|
RHO GTPases activate IQGAPs
|
|
RAF/MAP kinase cascade
|
|
Antigen activates B Cell Receptor (BCR) leading to generation of second messengersR-HSA-2514859:Inactivation, recovery and regulation of the phototransduction cascade
|
|
WikiPathways
|
Translocation of GLUT4 to the Plasma Membrane
|
|
Visual phototransduction
|
|
Fc epsilon receptor (FCERI) signaling
|
|
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
|
|
Signaling by the B Cell Receptor (BCR)
|
|
Inositol phosphate metabolism
|
|
DAG and IP3 signaling
|
|
Opioid Signalling
|
|
Muscle contraction
|
|
Metabolism of nitric oxide
|
|
Metabolism of carbohydrates
|
| References |
| REF 1 | How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. |
|---|
